BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BSX - US1011371077 - Common Stock
84 EUR
-3 (-3.45%)
Taking everything into account, BSX scores 5 out of 10 in our fundamental rating. BSX was compared to 65 industry peers in the Health Care Equipment & Supplies industry. While BSX has a great profitability rating, there are some minor concerns on its financial health. BSX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
BSX had positive earnings in the past year.
In the past year BSX had a positive cash flow from operations.
Of the past 5 years BSX 4 years were profitable.
BSX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BSX has a Return On Assets of 6.54%. This is in the better half of the industry: BSX outperforms 70.77% of its industry peers.
The Return On Equity of BSX (11.93%) is better than 69.23% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.09%, BSX is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BSX is below the industry average of 9.72%.
The 3 year average ROIC (6.59%) for BSX is below the current ROIC(8.09%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.09% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
1.3 Margins
The Profit Margin of BSX (14.42%) is better than 83.08% of its industry peers.
In the last couple of years the Profit Margin of BSX has declined.
BSX has a better Operating Margin (19.40%) than 81.54% of its industry peers.
BSX's Operating Margin has been stable in the last couple of years.
BSX has a Gross Margin of 68.57%. This is in the better half of the industry: BSX outperforms 75.38% of its industry peers.
BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
The number of shares outstanding for BSX has been increased compared to 1 year ago.
The number of shares outstanding for BSX has been increased compared to 5 years ago.
BSX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.65 indicates that BSX is not in any danger for bankruptcy at the moment.
BSX has a Altman-Z score of 5.65. This is amongst the best in the industry. BSX outperforms 86.15% of its industry peers.
BSX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as BSX would need 3.03 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.03, BSX is doing good in the industry, outperforming 73.85% of the companies in the same industry.
A Debt/Equity ratio of 0.48 indicates that BSX is not too dependend on debt financing.
BSX has a Debt to Equity ratio (0.48) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 5.65 |
ROIC/WACC0.99
WACC8.21%
2.3 Liquidity
A Current Ratio of 1.51 indicates that BSX should not have too much problems paying its short term obligations.
BSX has a Current ratio (1.51) which is in line with its industry peers.
A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
BSX has a worse Quick ratio (0.96) than 63.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
Looking at the last year, BSX shows a very strong growth in Revenue. The Revenue has grown by 21.62%.
The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.01% on average per year.
The Revenue is expected to grow by 12.51% on average over the next years. This is quite good.
EPS Next Y22.11%
EPS Next 2Y18.06%
EPS Next 3Y16.46%
EPS Next 5Y15.01%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.51%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 33.20, the valuation of BSX can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of BSX is on the same level as its industry peers.
BSX is valuated rather expensively when we compare the Price/Earnings ratio to 26.41, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 28.02, which means the current valuation is very expensive for BSX.
The rest of the industry has a similar Price/Forward Earnings ratio as BSX.
When comparing the Price/Forward Earnings ratio of BSX to the average of the S&P500 Index (35.40), we can say BSX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.2 | ||
| Fwd PE | 28.02 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit more expensive than the industry average as 61.54% of the companies are valued more cheaply.
BSX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BSX is cheaper than 61.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.01 | ||
| EV/EBITDA | 31.5 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of BSX may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 16.46% in the coming years.
PEG (NY)1.5
PEG (5Y)3.47
EPS Next 2Y18.06%
EPS Next 3Y16.46%
5. Dividend
5.1 Amount
BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BSX (12/4/2025, 7:00:00 PM)
84
-3 (-3.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.27%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap124.52B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Analysts86.34
Price Target111.15 (32.32%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)2.42%
PT rev (3m)3.83%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)2.28%
EPS NY rev (1m)1.75%
EPS NY rev (3m)1.75%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)2.15%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)1.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.2 | ||
| Fwd PE | 28.02 | ||
| P/S | 7.51 | ||
| P/FCF | 38.01 | ||
| P/OCF | 31.42 | ||
| P/B | 6.21 | ||
| P/tB | N/A | ||
| EV/EBITDA | 31.5 |
EPS(TTM)2.53
EY3.01%
EPS(NY)3
Fwd EY3.57%
FCF(TTM)2.21
FCFY2.63%
OCF(TTM)2.67
OCFY3.18%
SpS11.19
BVpS13.52
TBVpS-1.15
PEG (NY)1.5
PEG (5Y)3.47
Graham Number27.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.09% | ||
| ROICexc | 8.38% | ||
| ROICexgc | 28.19% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 5.65 |
F-Score6
WACC8.21%
ROIC/WACC0.99
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.11%
EPS Next 2Y18.06%
EPS Next 3Y16.46%
EPS Next 5Y15.01%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.51%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.37%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.
What is the valuation status of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.
How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?
BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.
Can you provide the financial health for BSX stock?
The financial health rating of BOSTON SCIENTIFIC CORP (BSX.DE) is 4 / 10.
What is the expected EPS growth for BOSTON SCIENTIFIC CORP (BSX.DE) stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 22.11% in the next year.